Contineum Therapeutics, Inc. (CTNM)
Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 20262 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Contineum Therapeutics, Inc.’s names, not what it holds today.
3 published
0 published
| Granted | Patent | Title | Field | Owner as printed |
|---|---|---|---|---|
| Aug 19, 2025 | 12,390,462 | Muscarinic acetylcholine M1 receptor antagonists | Pharmaceuticals | Contineum Therapeutics, Inc. |
| Aug 6, 2024 | 12,054,487 | Muscarinic acetylcholine M1 receptor antagonists | Pharmaceuticals | Contineum Therapeutics, Inc. |
| Published | Application | Title | Field | Owner as printed |
|---|---|---|---|---|
| Jun 5, 2025 | 2025/0179045 | LPAR1 ANTAGONISTS AND USES THEREOF | Organic fine chemistry | Contineum Therapeutics, Inc. |
| May 29, 2025 | 2025/0171455 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | Pharmaceuticals | Contineum Therapeutics, Inc. |
| Jan 23, 2025 | 2025/0026758 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | Pharmaceuticals | Contineum Therapeutics, Inc. |
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.